stockrowHarmony Biosciences Holdings, Inc.
HRMY Healthcare Biotechnology
Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024.
- Revenue
- +12.3%
- EPS
- −6.24%
- Free cash flow
- −29.4%
- Total debt
- −11.5%
Quarter to September 2026, against a year earlier
Follow HRMY
Alert me
Harmony Biosciences Holdings, Inc. (HRMY) Price to free cash flow
As of 6 November 2026, Harmony Biosciences Holdings, Inc. (HRMY) trades at a price to free cash flow of 6.8×. Over the past ten years it has ranged from 0.0× (March 2022) to 52.5× (June 2021); the current reading is higher than 31% of that period. That is below the Biotechnology industry median of 25.2× and below the Healthcare sector median of 20.5×.
Price to free cash flow, daily
Embed this chart
Annual newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| FY2025 | 7.0× | (36.22%) |
| FY2024 | 11.0× | 7.14% |
| FY2023 | 10.2× | (65.97%) |
| FY2022 | 30.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| Sep 2026 | 8.1× | 21.03% |
| Jun 2026 | 6.7× | 24.83% |
| Mar 2026 | 5.4× | (23.17%) |
| Dec 2025 | 7.0× | 13.17% |
| 23 more quarters | Free account |
Against its own ten years
Price to free cash flow against peers
| Company | Price to free cash flow |
|---|---|
| TRVI Trevi Therapeutics, Inc. compare | n/m |
| MESO Mesoblast Limited compare | n/m |
| MAZE Maze Therapeutics, Inc. compare | n/m |
| VIR Vir Biotechnology, Inc. compare | n/m |
| TRAX First Tracks Biotherapeutics, Inc. compare | n/m |
| REPL Replimune Group, Inc. compare | n/m |
| HRMY Harmony Biosciences Holdings, Inc. | 6.8× |
| SRPT Sarepta Therapeutics, Inc. compare | 11.1× |
| FTRE Fortrea Holdings Inc. compare | 12.3× |
| Biotechnology industry median | 25.2× |
| Healthcare sector median | 20.5× |
| Market median | 14.0× |
What Price to free cash flow is
Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.
Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))